|
2025
|
Invention
|
Shp2 and egfr inhibitors for the treatment of chordoma. The present disclosure provides methods o... |
|
|
Invention
|
Kras inhibitors. The present embodiments provide compounds of Formula I, compositions of the comp... |
|
2024
|
Invention
|
Compositions and methods for treating cancer. The disclosure relates to methods of treating gliob... |
|
|
Invention
|
Macrocyclic ulk1/2 inhibitors and their use thereof. Described herein are macrocycle compounds th... |
|
|
Invention
|
Thiophene ulk1/2 inhibitors and their use thereof. Described herein are compounds that are ULK1/2... |
|
|
Invention
|
Kras inhibitors. The present embodiments provide compounds of Formula (I), compositions of the co... |
|
|
Invention
|
Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy. A pharmaceutical combination ... |
|
|
Invention
|
Raf inhibitor and kras g12c inhibitor combination therapy. A pharmaceutical combination including... |
|
2023
|
Invention
|
Erk1/2 inhibitor polymorph forms. Disclosed herein are polymorph forms of (S)-N-(2-amino-l-(3-chl... |
|
|
Invention
|
Kras inhibitor conjugates. The present embodiments provide compounds of Formula I, compositions o... |
|
|
Invention
|
Tricyclic pyridones and pyrimidones.
Compounds with KRAS G12C inhibitory active are disclosed an... |
|
|
Invention
|
Tricyclic pyridones and pyrimidones. Compounds with KRAS G12C inhibitory active are disclosed and... |
|
|
Invention
|
Tricyclic pyrimidones. Compounds with KRAS G12C inhibitory active are disclosed and methods of us... |
|
|
Invention
|
Antibodies against egfr and their uses.
Described herein are antibodies that bind EGFR domain II... |
|
|
Invention
|
Antibodies against egfr and their uses. Described herein are antibodies that bind EGFR domain II ... |
|
2022
|
Invention
|
Thiophene ulk1/2 inhibitors and their use thereof.
Described herein are compounds that are ULK1/... |
|
|
Invention
|
Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors.
The pre... |
|
|
Invention
|
Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors. The pres... |
|
|
Invention
|
Egfr inhibitor polymorph forms. SNN-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7... |
|
|
Invention
|
Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy.
The present invention rela... |
|
|
Invention
|
Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy. The present invention relat... |
|
|
Invention
|
Selective kras inhibitors. The present embodiments provide compounds of Formula (I), compositions... |
|
|
Invention
|
Erk1/2 and egfr inhibitors combination therapy.
The present disclosure relates generally to the ... |
|
|
Invention
|
Erk1/2 and shp2 inhibitors combination therapy.
The present disclosure relates generally to the ... |
|
|
Invention
|
Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer.
The present disclo... |
|
|
Invention
|
Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy.
The present disclosure relate... |
|
|
Invention
|
Erk1/2 and kras g12c inhibitors combination therapy.
The present disclosure relates generally to... |
|
|
Invention
|
Erk1/2 and egfr inhibitors combination therapy. The present disclosure relates generally to the u... |
|
|
Invention
|
Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy. The present disclosure relates... |
|
|
Invention
|
Erk1/2 and shp2 inhibitors combination therapy. The present disclosure relates generally to the u... |
|
|
Invention
|
Erk1/2 and kras g12c inhibitors combination therapy. The present disclosure relates generally to ... |
|
|
Invention
|
Erk1/2 and cdk4/6 inhibitors combination therapy. The present disclosure relates generally to the... |
|
|
Invention
|
Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer. The present disclos... |
|
|
Invention
|
Tricyclic kras inhibitors. The present embodiments provide compounds of Formula (I), compositions... |
|
|
Invention
|
Tricyclic pyridones and pyrimidones.
A compound of Formula (I) is provided: (I) where the variab... |
|
|
Invention
|
Amide and urea-containing tricyclic kras inhibitors.
The present embodiments provide compounds o... |
|
|
Invention
|
Kras inhibitor conjugates.
The present application provides conjugates of protein-binding ligand... |
|
|
Invention
|
Uses of heterocyclic inhibitors of erk1/2.
The use of heterocyclic inhibitors of ERK1/2 for trea... |
|
|
G/S
|
venture capital services, namely, providing financing to entrepreneurs and emerging and start-up ... |
|
|
G/S
|
philanthropic services, namely, providing charitable grants to others for use in environmental, s... |
|
2021
|
Invention
|
Combination therapies for the treatment of cancer.
The present disclosure provides methods of tr... |
|
|
Invention
|
Compositions and methods for treating cancer.
The present disclosure relates to compounds that a... |
|
|
G/S
|
Anti-cancer preparations; pharmaceutical and biological preparations for the treatment of cancer;... |
|
|
G/S
|
Anti-cancer preparations; pharmaceutical preparations and substances for the treatment of cancer;... |
|
2020
|
G/S
|
Drug discovery services; pharmaceutical research and development; scientific research for medical... |
|
|
G/S
|
Research and development in the fields of pharmaceuticals, cancer, and oncology treatments and cu... |
